TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33378424

Group type: EXPERIMENTAL
Intervention: Exercise training for 24 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (uninfected, n=21)
Number of subjects: 18
Study: 33378612

Group type: COMPARATOR
Intervention: Vedolizumab (induction phase)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Vedolizumab (maintenance phase, every 4 weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Vedolizumab (maintenance phase, every 8 weeks)
Number of subjects: 51
Study: 33380172

Group type: EXPERIMENTAL
Intervention: Higher 12-lipoxygenase oxylipin plasma concentrations in premenopausal females
Number of subjects: 0
Study: 33380478

Group type: EXPERIMENTAL
Intervention: Intraocular pressure-lowering therapy (specific details not provided)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Detailed ophthalmic examinations (specific details not provided)
Number of subjects: 813
Study: 33380480

Group type: EXPERIMENTAL
Intervention: Quality Indicators (QIs) for Cardiac Rehabilitation (CR)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Quality Indicators (QIs) identified through a nationwide questionnaire survey
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Quality Indicators (QIs) developed by a consensus panel
Number of subjects: 165
Study: 33380512

Group type: EXPERIMENTAL
Intervention: RHC (Right Heart Catheterization)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 55
Study: 33380924

Group type: EXPERIMENTAL
Intervention: Combined CHADS-BLED score in TF TAVR patients with atrial fibrillation (AF)
Number of subjects: 1329

Group type: EXPERIMENTAL
Intervention: Combined CHADS-BLED score in TF TAVR patients with AF
Number of subjects: 1329
Study: 33381248

Group type: EXPERIMENTAL
Intervention: PacBio RS II platform
Number of subjects: 0

Group type: COMPARATOR
Intervention: MiSeq platform
Number of subjects: 0
Study: 33381755

Group type: EXPERIMENTAL
Intervention: Serum neurofilament light protein
Number of subjects: 0
Study: 33381769

Group type: EXPERIMENTAL
Intervention: Carpal tunnel decompression surgery
Number of subjects: 855832
Study: 33382032

Group type: EXPERIMENTAL
Intervention: Positive airway pressure therapy; Treatment adherence rate: 55% at 1 year.
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Positional therapy and opioids/sedative reduction; Treatment received by the rest of the patients with sleep apnea.
Number of subjects: 204

Group type: COMPARATOR
Intervention: Not applicable; High refusal rate for treatment.
Number of subjects: 204
Study: 33382039

Group type: EXPERIMENTAL
Intervention: Mobile app (¡Hola Bebé, Adiós Diabetes!)
Number of subjects: 21
Study: 33382121

Group type: EXPERIMENTAL
Intervention: Permanent atrial fibrillation
Number of subjects: 121

Group type: COMPARATOR
Intervention: Decompensated CHF without permanent atrial fibrillation
Number of subjects: 121
Study: 33382332

Group type: EXPERIMENTAL
Intervention: Avoidance coping strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endurance coping strategies
Number of subjects: 0
Study: 33382405

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) initiated on the day of enrollment for 171 (87.7%) participants.
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Nonreactive or indeterminate HIV antibody on the Geenius assay combined with ARCHITECT S/CO ≥10.
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Novel AEHI criteria incorporating ARCHITECT S/CO.
Number of subjects: 195
Study: 33382877

Group type: EXPERIMENTAL
Intervention: T2D+OA
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: CON+OA
Number of subjects: 66

Group type: COMPARATOR
Intervention: T2D-OA
Number of subjects: 66

Group type: COMPARATOR
Intervention: CON-OA
Number of subjects: 66
Study: 33382891

Group type: EXPERIMENTAL
Intervention: 24-hour urinary 5-hydroxyindolacetic acid (24u5HIAA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: overnight urinary 5HIAA (Ou5HIAA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: plasmatic 5HIAA (p5HIAA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 24u5HIAA
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ou5HIAA
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: p5HIAA
Number of subjects: 80
Study: 33383007

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation using the CoreValve and Evolut R devices
Number of subjects: 202
Study: 33383315

Group type: EXPERIMENTAL
Intervention: Deep learning-based classification using a multi-layer deep convolutional neural network (CNN) trained on FAF images.
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Deep learning-based classification using a multi-layer deep convolutional neural network (CNN) with 10-fold cross-validation.
Number of subjects: 314
Study: 33383350

Group type: EXPERIMENTAL
Intervention: 400 mg of testosterone cypionate intramuscularly every 28 days concurrent with a luteinising hormone-releasing hormone agonist/antagonist
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: bipolar androgen therapy (BAT)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: after progression on BAT
Number of subjects: 29
Study: 33383395

Group type: EXPERIMENTAL
Intervention: Bone-conducted acoustic stimulation
Number of subjects: 8
Study: 33383486

Group type: EXPERIMENTAL
Intervention: Apatinib
Number of subjects: 21
Study: 33383646

Group type: EXPERIMENTAL
Intervention: ABL001 with paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ABL001 with irinotecan
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABL001
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irinotecan
Number of subjects: 0
Study: 33384331

Group type: EXPERIMENTAL
Intervention: Viewing pictures of foods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Viewing food pictures
Number of subjects: 0
Study: 33384402

Group type: EXPERIMENTAL
Intervention: COVID-19-related prenatal stress exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retrospective data on COVID-19-related stress during pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Videotaped semistructured interaction at 12 months
Number of subjects: 0
Study: 33384640

Group type: EXPERIMENTAL
Intervention: 8-week visual art training program
Number of subjects: 53
Study: 33384959

Group type: EXPERIMENTAL
Intervention: Web-based supportive care program
Number of subjects: 0
Study: 33385020

Group type: EXPERIMENTAL
Intervention: Probiotics; specific dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; specific details not available
Number of subjects: 0
Study: 33385126

Group type: EXPERIMENTAL
Intervention: ENGBD
Number of subjects: 22

Group type: COMPARATOR
Intervention: PTGBD
Number of subjects: 22
Study: 33385266

Group type: EXPERIMENTAL
Intervention: Supportive housing with comprehensive health-related services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stakeholder strategies in supportive housing
Number of subjects: 0
Study: 33385520

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor therapy
Number of subjects: 1214

Group type: EXPERIMENTAL
Intervention: Targeted therapy
Number of subjects: 1214

Group type: EXPERIMENTAL
Intervention: Overall response rate
Number of subjects: 1214

Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events (TRAEs)
Number of subjects: 1214
Study: 33386133

Group type: EXPERIMENTAL
Intervention: Canonical variates related to multiple symptom dimensions (irritability, ADHD, anxiety)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Canonical variates specific to anxiety
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Functional connectivity modeled as partial correlations among 216 brain areas
Number of subjects: 508
Study: 33386410

Group type: EXPERIMENTAL
Intervention: Employed participants
Number of subjects: 2481

Group type: EXPERIMENTAL
Intervention: Household size
Number of subjects: 2481

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 2481

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2481
Study: 33386970

Group type: EXPERIMENTAL
Intervention: Acromegaly group
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 33387056

Group type: EXPERIMENTAL
Intervention: DeRidder Burst-SCS stimulation
Number of subjects: 0
Study: 33387153

Group type: EXPERIMENTAL
Intervention: Tetanus-induced ANI variation (5 s tetanus at 70 mA, 50 Hz) before laryngoscopy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Tetanus-induced ANI variation
Number of subjects: 35
Study: 33387217

Group type: EXPERIMENTAL
Intervention: Hybrid intradialytic exercise training (aerobic cycling and resistance training) for 9 months
Number of subjects: 20
Study: 33387276

Group type: EXPERIMENTAL
Intervention: Artificial intelligence-derived screening tool for food addiction (FA)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Naive Bayes classification
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: 3-item nomogram
Number of subjects: 176
Study: 33387373

Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM) with the InterStim™ system
Number of subjects: 221
Study: 33387381

Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs)
Number of subjects: 1601
Study: 33387490

Group type: EXPERIMENTAL
Intervention: APX005M (sotigalimab) with gemcitabine plus nab-paclitaxel, with or without nivolumab
Number of subjects: 30
Study: 33388360

Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: External Radiation Therapy
Number of subjects: 650
Study: 33388386

Group type: EXPERIMENTAL
Intervention: Patients with diabetes
Number of subjects: 603

Group type: COMPARATOR
Intervention: Patients without diabetes
Number of subjects: 603
Study: 33388955

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic (VATS) resection
Number of subjects: 73
Study: 33388985

Group type: EXPERIMENTAL
Intervention: Cochlear implant fitting methodology and parameters
Number of subjects: 97
Study: 33389082

Group type: EXPERIMENTAL
Intervention: Slower eating rate
Number of subjects: 33

Group type: COMPARATOR
Intervention: Faster eating rate
Number of subjects: 33
Study: 33389140

Group type: EXPERIMENTAL
Intervention: Breaks in sedentary time per sedentary hour (BST-ST)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bouts of sedentary time longer than 15 minutes (BSB > 15 min)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cardiorespiratory fitness (CRF)
Number of subjects: 80
Study: 33389209

Group type: EXPERIMENTAL
Intervention: Osmolality-based normalization
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Specific dilution prior to analysis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of various normalization methods
Number of subjects: 40
Study: 33389355

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure performance measurement variables (MDPE and MDAPE) during cardiac surgery
Number of subjects: 1203

Group type: EXPERIMENTAL
Intervention: Intraoperative hypotension measured by performance measurement variables
Number of subjects: 1203

Group type: EXPERIMENTAL
Intervention: Kaplan-Meier survival curves
Number of subjects: 1203
Study: 33389379

Group type: EXPERIMENTAL
Intervention: Assisted reproductive technology (ART) after ovarian tissue transplantation (OTT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Spontaneous conception
Number of subjects: 11
Study: 33389388

Group type: EXPERIMENTAL
Intervention: Ulixertinib (10 to 900 mg in dose escalation cohort, 600 mg in 21-day cycles in expansion cohort)
Number of subjects: 135
Study: 33389459

Group type: EXPERIMENTAL
Intervention: Low salt-low protein diet (0.6 g/kg-day) supplemented with keto-analogues (sLPD) under intensive nutritional counselling
Number of subjects: 92
Study: 33389656

Group type: EXPERIMENTAL
Intervention: Carfilzomib (27 mg/m²) administered twice weekly
Number of subjects: 0
Study: 33390187

Group type: EXPERIMENTAL
Intervention: Education on one occasion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Education staged and supported by a dietitian
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 33390782

Group type: EXPERIMENTAL
Intervention: Rapamycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Torin-2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RIST treatment protocol (combination of Rapamycin and Dasatinib with Irinotecan and Temozolomide)
Number of subjects: 0
Study: 33390917

Group type: EXPERIMENTAL
Intervention: Anodal tDCS on the anterior cingulate cortex
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study: 33391002

Group type: EXPERIMENTAL
Intervention: 1 ml of 5% dextrose water
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 2 ml of 5% dextrose water
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 4 ml of 5% dextrose water
Number of subjects: 63

Group type: COMPARATOR
Intervention: Electrophysiological studies
Number of subjects: 63

Group type: COMPARATOR
Intervention: Median nerve CSA
Number of subjects: 63
Study: 33391029

Group type: EXPERIMENTAL
Intervention: Vigorous physical activity (PA)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Increased systolic blood pressure (BP)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 262
Study: 33391164

Group type: EXPERIMENTAL
Intervention: CareToy-Revised (CareToy-R) intervention for 8 weeks
Number of subjects: 19
Study: 33392384

Group type: EXPERIMENTAL
Intervention: CCTA imaging
Number of subjects: 193
Study: 33392438

Group type: EXPERIMENTAL
Intervention: Patient and family co-developed participant information
Number of subjects: 0
Study: 33392485

Group type: EXPERIMENTAL
Intervention: INO-4800 1.0 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: INO-4800 2.0 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: INO-4800
Number of subjects: 40
Study: 33392493

Group type: EXPERIMENTAL
Intervention: Factors 1 (Interferon-gamma, IL-4, IL-7, IL-10, IL-12, IL-17A, IL-21, IL-23, MIP-1α, MIP-1β, TNF-α, GM-CSF)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Factors 2 (IL-5, IL-6, IL-8, IL-13)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Factors 1, 2 and 3 (C-Reactive protein, IL-1β, IL-2, MIP-3α)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Numerous individual inflammatory mediators (Interferon-gamma, GM-CSF, IL-4, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17A, IL-21, IL-23, MIP-1α, MIP-1β)
Number of subjects: 358
Study: 33392541

Group type: EXPERIMENTAL
Intervention: Fish oil-containing lipid injectable emulsion (Smoflipid 20% lipid emulsion) administered at doses of 1.0 to 1.6 g/kg within 48 hours of enrollment.
Number of subjects: 10
Study: 33392749

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg once daily
Number of subjects: 34
Study: 33392770

Group type: EXPERIMENTAL
Intervention: Care pathway (PP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard care (NPP)
Number of subjects: 48
Study: 33392801

Group type: EXPERIMENTAL
Intervention: Pemafibrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statins
Number of subjects: 0
Study: 33393377

Group type: EXPERIMENTAL
Intervention: Treatment intervention
Number of subjects: 0
Study: 33393488

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 277

Group type: COMPARATOR
Intervention: Nonstatin users (Control)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Atorvastatin and Nonstatin users (Control)
Number of subjects: 277
Study: 33394100

Group type: EXPERIMENTAL
Intervention: High intensity aerobic exercise for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiparkinsonian medication
Number of subjects: 0
Study: 33394121

Group type: EXPERIMENTAL
Intervention: Higher dietary zinc intake (8.4±4.5 mg/day) from non-red meat sources
Number of subjects: 5186

Group type: COMPARATOR
Intervention: Dietary zinc intake from red meat sources
Number of subjects: 5186
Study: 33394138

Group type: EXPERIMENTAL
Intervention: Tracker
Number of subjects: 24

Group type: COMPARATOR
Intervention: Diary
Number of subjects: 24
Study: 33394284

Group type: EXPERIMENTAL
Intervention: PSMA ligand
Number of subjects: 42
Study: 33394595

Group type: EXPERIMENTAL
Intervention: Intraoperative assessment of allograft microperfusion using indocyanine green (ICG) fluorescence angiography
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: ICG Ingress
Number of subjects: 128
Study: 33394679

Group type: EXPERIMENTAL
Intervention: HIV-infected women not on ART
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Baseline vaginal inflammation
Number of subjects: 207
Study: 33394722

Group type: EXPERIMENTAL
Intervention: Maintenance therapy using modern agents (e.g., oral hypomethylating agents, protein modifiers, FLT3, IDH1/2, BCL-2, immune checkpoint inhibitors)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized, placebo-controlled trials of maintenance therapy
Number of subjects: 0
Study: 33394878

Group type: EXPERIMENTAL
Intervention: Neuropathic pain (NeuP)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Conditioned pain modulation
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Child-parent QoL scores
Number of subjects: 66
Study: 33394925

Group type: EXPERIMENTAL
Intervention: Increasing myopic spherical refractive errors
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: Increasing astigmatic refractive errors
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: Higher uncorrected hyperopic refractive error
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: logMAR distance acuity of 0.20 to 0.32
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: Distance acuity alone
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: Higher myopic and/or astigmatic refractive errors
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: Reduction in acuity per diopter of cylindrical error
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: Distance acuity
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: Accommodation
Number of subjects: 2212
Study: 33394942

Group type: EXPERIMENTAL
Intervention: Healthcare professional priorities
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Parent priorities
Number of subjects: 144

Group type: COMPARATOR
Intervention: Comparison of priorities
Number of subjects: 144
Study: 33395032

Group type: EXPERIMENTAL
Intervention: Selumetinib (Koselugo) for plexiform neurofibromas (pNF)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Selumetinib (Koselugo) for low-grade gliomas (LGG)
Number of subjects: 71
Study: 33395094

Group type: EXPERIMENTAL
Intervention: Rapid multiplex-PCR assays for pneumonia diagnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapid multiplex-PCR assays
Number of subjects: 0
Study: 33395098

Group type: EXPERIMENTAL
Intervention: Novel genetic therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Understanding of UBE3A and its role in neuronal development
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Greater understanding of the pathophysiology of different phenotypes
Number of subjects: 0
Study: 33395354

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33395553

Group type: EXPERIMENTAL
Intervention: Noninvasive Ventilatory Support
Number of subjects: 0
Study: 33397139

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Midazolam (0.045 mg/kg)
Number of subjects: 30
Study: 33397330

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 58
Study: 33397350

Group type: EXPERIMENTAL
Intervention: Extended scope physiotherapists (ESP)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Orthopaedic surgeons (OS)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: ESP and OS combined
Number of subjects: 69
Study: 33397382

Group type: EXPERIMENTAL
Intervention: Care pathway (CP) implementation
Number of subjects: 381
Study: 33397509

Group type: EXPERIMENTAL
Intervention: Pharmacist supplemented care
Number of subjects: 356

Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 356
Study: 33397511

Group type: EXPERIMENTAL
Intervention: Sawyer® PointONE™ filters installed in homes
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sawyer® PointONE™ filters installed in schools
Number of subjects: 16
Study: 33398064

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 47
Study: 33398260

Group type: EXPERIMENTAL
Intervention: Symptom management care pathways
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33398536

Group type: EXPERIMENTAL
Intervention: Primary glioma cell lines
Number of subjects: 12
Study: 33398548

Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI) + White Light (WL)
Number of subjects: 84

Group type: COMPARATOR
Intervention: White Light (WL)
Number of subjects: 84
Study: 33398714

Group type: EXPERIMENTAL
Intervention: Moderate hyperoxemia (PaO2: 120-200 mmHg, n = 121)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Severe hyperoxemia (PaO2: > 200 mmHg, n = 74)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Normoxia (PaO2 < 120 mmHg, n = 52)
Number of subjects: 247
Study: 33399311

Group type: EXPERIMENTAL
Intervention: PrEP candidates (51.8% precontemplative, 48.2% contemplative)
Number of subjects: 1398

Group type: EXPERIMENTAL
Intervention: PrEP action (3.1% reached stage 4; prescribed PrEP)
Number of subjects: 1398

Group type: EXPERIMENTAL
Intervention: PrEP maintenance (87% adherence to 4+ doses per week)
Number of subjects: 1398

Group type: EXPERIMENTAL
Intervention: Factors associated with reaching later stages
Number of subjects: 1398
Study: 33399372

Group type: EXPERIMENTAL
Intervention: mini-fluid challenge (mini-FC) of 100 ml over 1 min
Number of subjects: 103

Group type: COMPARATOR
Intervention: end-expiratory occlusion test (EEOT20)
Number of subjects: 103

Group type: COMPARATOR
Intervention: end-expiratory occlusion test (EEOT30)
Number of subjects: 103
Study: 33399375

Group type: EXPERIMENTAL
Intervention: Preoperative moderate to severe anaemia
Number of subjects: 8264
Study: 33399383

Group type: EXPERIMENTAL
Intervention: 50% inhaled N2O
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 25% inhaled N2O
Number of subjects: 40
Study: 33399433

Group type: EXPERIMENTAL
Intervention: Open schools and day-care facilities
Number of subjects: 0
Study: 33399511

Group type: EXPERIMENTAL
Intervention: MRI-guided focused ultrasound-induced BBB opening targeting the hippocampus and entorhinal cortex, performed three times at 2-week intervals using a 220-kHz transducer and intravenous microbubble contrast agent.
Number of subjects: 3